Radiat Oncol J.  2017 Sep;35(3):289-294. 10.3857/roj.2017.00339.

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma

Affiliations
  • 1Department of Radiation Oncology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea. yskim@jejunuh.co.kr
  • 2Department of Nuclear Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
  • 3Department of Radiation Oncology, Inje University Busan Paik Hospital, Inje University of Medicine, Busan, Korea.

Abstract

Sorafenib is widely used for unresectable and metastatic hepatocellular carcinomas. Radiation recall dermatitis (RRD) is an acute inflammatory reaction confined to previously irradiated skin that occurs after the administration of certain drugs. RRD after sorafenib treatment is rare; five cases have been reported thus far. We describe a 44-year-old man irradiated for chest wall bone metastasis from hepatocellular carcinoma. Eight days after radiotherapy completion, systemic therapy for metastatic hepatocellular carcinoma was initiated with sorafenib treatment. Eleven days after starting sorafenib, the patient complained of erythematous rash with pruritus in the chest wall, in a location consistent with the previous radiation field. Sorafenib was continued at the same dose, despite the RRD. The skin reaction subsided over the next 2 weeks without any medical intervention.

Keyword

Sorafenib; Radiotherapy; Radiation recall dermatitis; Hepatocellular carcinoma

MeSH Terms

Adult
Carcinoma, Hepatocellular*
Exanthema
Humans
Neoplasm Metastasis
Pruritus
Radiodermatitis*
Radiotherapy
Skin
Thoracic Wall
Full Text Links
  • ROJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr